Newsletter · 2026-08-28 · Ashutosh Agarwal

The Money Gets Squeezed Out of Government Healthcare as Innovation Races Ahead - Healthcare Podcast Weekly Digest - Week of August 28, 2026

Healthcare Podcast Weekly Digest for the week of August 22 to 28, 2026. Podcast synthesis on the HR1 Medicaid payment cuts that hit hospital revenue in early 2027, a record Medicare Advantage retreat with plan terminations rising to 10 percent of members, Eli Lilly pairing an 800 million dollar guilty plea with a 3.8 billion dollar buying spree, and a run of approvals from an mRNA cancer vaccine to a blood-draw robot.

Healthcare Podcast Weekly Digest

Week of August 28, 2026: The Money Gets Squeezed Out of Government Healthcare as Innovation Races Ahead

The week in one breath

This was a week where almost nothing that moved healthcare stocks came out of an earnings report. Instead it was courtrooms, a guilty plea, a takeover, drug approvals, and, running underneath all of it, a slow, grinding rewrite of how the U.S. government pays for care.

The single biggest healthcare story on the podcasts was Eli Lilly (LLY) having, as one show put it, a week that ran in two directions at once: it pled guilty to an old marketing case and paid a fine, then in the very same seven days went on a shopping spree to buy itself a second act beyond weight-loss drugs, and raised its revenue forecast for the year. Around that, three separate podcasts kept circling the same theme: the money is getting squeezed out of government healthcare. Hospitals are bracing for deep Medicaid payment cuts. Insurers are pulling out of Medicare Advantage markets at a record pace. And ordinary Americans are facing another double-digit jump in insurance premiums.

At the same time, the innovation side of the sector had a genuinely exciting week: an mRNA cancer vaccine, an FDA-cleared robot that draws your blood, a pill that mimics exercise, and a wave of new oral drugs trying to replace injections. The tension between "healthcare is getting less affordable and less accessible" and "healthcare technology is advancing fast" was the real story of the week.

Key people this week

Hot topics

Eli Lilly (LLY), the busiest name of the week

Lilly showed up on multiple podcasts and across the news, and the picture was a company doing several big things at once:

• A guilty plea and an ~$800 million check. On the Telltales podcast, the hosts explained Lilly agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act and pay roughly $800 million over how it once promoted the antipsychotic Zyprexa. Co-host Marcus Graham put the number in perspective: against Lilly's roughly $21 billion of yearly free cash flow, "$800 million… that's about two weeks of production." In other words, a headline-grabbing fine that barely dents the business.
• A buying spree to diversify beyond weight loss. In the same week, per the Telltales podcast, Lilly announced deals to buy three vaccine and infectious-disease companies for $3.8 billion, and put $50 million upfront into an mRNA cancer partnership with CureVac that could be worth up to $1.8 billion. The logic, as Graham framed it: "that's Lilly buying a second act while GLP-1 is still paying for everything."
• Higher guidance. Lilly raised its full-year revenue forecast to $85–$87 billion.
• The weight-loss pill goes to Britain. On Aug 24 Lilly launched its once-daily weight-loss pill Foundayo (orforglipron) in the UK, the first European country to get the oral version. It starts on private prescription, expected to cost between £100 and £120 a month (about $136). Shares dipped about 1.2% that day.
• Proof the pills actually save money. On Aug 26 Lilly released a real-world study (published in Diabetes, Obesity and Metabolism) of adults over 55 on its injectable Zepbound. Staying on the drug cut healthcare costs by up to 15% ($181 per patient per month) at six months, and up to 38% ($607 per patient per month) at twelve months, versus similar untreated adults, driven by fewer hospital and ER visits. For seniors, the savings began to exceed the cost of the drug after a year. Despite the good news, Lilly shares fell 3.3% that afternoon on a broadly weak day for healthcare.
• A tech footnote: Needham raised its price target on Veeva to $310 (from $270), and named Lilly as one of Veeva's notable software wins.

The GLP-1 and obesity race, and the move to pills

The obesity-drug boom is no longer just about who has the strongest injection. This week the conversation shifted to two things: pills instead of shots, and next-generation drugs that combine multiple mechanisms.

• On the Schwab Network podcast, Protagonist Therapeutics (PTGX) CEO Dinesh Patel argued the whole industry is moving from injectables to pills, pointing to the arrival of oral semaglutide as proof: "the massive shift towards oral peptides… is a clear indication of what… the patients would prefer, especially for… chronic indications." Protagonist is developing its own oral "triple-G" obesity drug, a pill version of the kind of triple-hormone approach that Lilly's injectable retatrutide has pioneered. Patel called Lilly's retatrutide "probably the most weight loss effective drug that is out there."
• Background reporting this week noted Lilly is scaling its oral pill (orforglipron) to ease supply, while Novo Nordisk (NVO) is pushing its combination drug CagriSema for obesity, sleep apnea, and knee arthritis pain.

Hospitals, a squeeze coming, not here yet

On the Health:Further podcast, healthcare operator Paul Kaplman warned that last year's big budget law (which he and the host called the "one big beautiful bill," or HR1) will start hitting hospital revenue in early 2027. He singled out HCA Healthcare (HCA) as the operator with the least exposure to unpaid bills, "because of just their markets that they're in," but said even HCA is "feeling the pinch." His expectation: more hospital closures, and more quietly, hospitals dropping money-losing service lines like maternity (OB), neonatal intensive care (NICU), and burn units. As he put it, "the building with the sign on it is still there… but they don't have OB. They don't have NICU."

Managed care and Medicare Advantage, a record retreat

The clearest hard data of the week came from The Seven Figures Or Bust podcast, which follows the Medicare insurance business closely. The numbers on how fast insurers are backing out of Medicare Advantage (the private version of Medicare) are striking:

• The number of standard Medicare Advantage plans available fell about 10% nationally in one year, from 3,719 in 2025 to 3,373 in 2026 (citing Oliver Wyman data).
• The average senior went from a choice of 36 plans at the 2024 peak to 32 in 2026 (citing the Kaiser Family Foundation).
• Plan terminations, where an insurer pulls a plan out of an area entirely, jumped from about 1% of members a year (the 2018–2024 average, per Johns Hopkins) to 6.9% in 2025 and 10% in 2026. The 2026 plan year saw a record 2.9 million members terminated; roughly another 2 million are expected to lose their plan heading into 2027.
• UnitedHealthcare (UNH) and Humana are "exiting more counties than they're entering," a two-year trend. In hard-hit states like Vermont, Wyoming, New Hampshire, and North Dakota, up to 60% of Medicare Advantage members saw their plan disappear. Vermont went from 8 plans to just 3 after UnitedHealthcare and Blue Advantage pulled out.

The host's read: this is a painful but temporary "2 to 3 year correction" as insurers cut back after years of too many thin-margin plans, not a permanent collapse of the business.

This lines up with UnitedHealth's own stock story this week. On Aug 27, Erste Group downgraded UNH to Hold from Buy, citing "very low" revenue growth in 2026 and 2027 (below the sector) and a price-to-earnings ratio "significantly higher" than peers.

Key debates (bull vs. bear)

Eli Lilly: is the diversification smart, or a sign of worry?

• Bull: Lilly is using its GLP-1 cash machine to buy a future beyond weight loss (vaccines, infectious disease, mRNA cancer), shrugged off an $800M fine that's a rounding error, and raised guidance to $85–$87 billion. The Telltales hosts said the vaccine deals are "the ones I'd actually underwrite."
• Bear: The stock is priced for perfection, the Telltales team pegged it at roughly 58 times trailing free cash flow, and the market keeps selling off even good news (shares fell 3.3% on a positive cost-savings study). If GLP-1 competition intensifies (Novo's CagriSema, a coming wave of pills), that premium is hard to defend.

Medicare Advantage: correction or structural decline?

• Bull (correction): On The Seven Figures Or Bust podcast, the argument is that insurers had far too many overlapping plans; culling them is healthy, government payment rates ("CMS has continued to raise our commissions") are improving, and plan counts should stabilize by 2027.
• Bear (structural): Record terminations, two straight years of UnitedHealthcare and Humana leaving counties, and 2 million more seniors losing coverage suggests the economics of Medicare Advantage are genuinely broken, not just crowded, and Wall Street's UNH downgrade this week echoes that worry.

Hospitals: manageable headwind or a cliff?

• Bull: The Medicaid payment cuts don't bite for about a year (per the HIMSSCast discussion), giving hospitals time to get more efficient, and consolidation and mergers can save struggling facilities. Kaplman on Health:Further noted a "merger is much better than a closure."
• Bear: On the HIMSSCast podcast, Holland & Knight's Robert Bradner warned the special payments being cut can be "20 percent of your Medicaid revenue," phased down 10% a year, on top of more uninsured patients, a combination that could push weaker hospitals under, especially rural and safety-net ones.

Is "Medicare for All" suddenly plausible? On the Health:Further podcast, Kaplman made a striking political call: with premiums rising and coverage shrinking, "Could it set up a scenario where the American public is angry enough to support Medicare for all? I think it's got more probability than it's ever had in our lifetime… maybe that's fifty one forty nine." For healthcare investors, that's a long-tail policy risk worth filing away ahead of the November midterms.

Emerging themes

• Pills are eating injections. The loudest new investment theme this week was the shift from injectable drugs to oral ones, in obesity, but also in immune diseases like psoriasis and Crohn's. Protagonist's CEO on the Schwab Network podcast framed his whole company around cracking the hard chemistry of making a pill do what an injection does, targeting a market "over $100 billion." Watch this as the next battleground in the GLP-1 wars.
• AI and robots quietly entering the clinic. Several podcasts touched this. On Health:Further, the hosts flagged that the FDA has authorized the first standalone blood-draw robot, one operator can run up to three machines, and it uses infrared and ultrasound to find veins (already in use in Europe). They also noted 85% of hospitals using the Epic medical-records system are now using its AI tools. And the FDA has opened a comment period on a new, lighter framework for approving AI-powered devices, leaning more on monitoring devices after they launch than testing everything upfront.
• Autonomous surgery as an answer to the surgeon shortage. On the DeviceTalks podcast, the CEO of a startup called Inner Logic (formerly Semaphore) laid out a thesis that there simply aren't enough surgeons to reach every patient, "we have demand in excess of supply," and that software which can test surgical robots against thousands of "virtual patients" is the path to machines that don't just follow a surgeon's plan but "perceive… reason, and… adapt." It's early and privately held, but it's the same demand backdrop that supports robotic-surgery leaders like Intuitive Surgical.
• Retailers pushing into healthcare. On Health:Further, the hosts noted Costco is entering Medicare Advantage sales (partnering with SCAN Group, starting in three markets) even as traditional insurers flee, a bet on using healthcare to keep members loyal rather than on the insurance margins themselves.
• The "convenience" frontier, with a health cost question. The Health:Further podcast covered an experimental "exercise pill" that just cleared its first human safety test (it mimics the body's response to exercise). The hosts were intrigued but wary about a future where people stack a weight-loss drug on top of an exercise-replacement pill: "We're headed in a convenient direction, but I'm not sure in the long run it's good for whole health."

Deals and M&A tracker

• Curium to acquire Lantheus (LNTH), ~$8 billion. On the Telltales podcast, the hosts detailed a full takeover: Curium agreed to buy Lantheus for $102.50 a share in cash, plus contingent value rights (extra payments tied to future milestones) worth up to $12 more, a total potential value around $8 billion, expected to close in the first half of 2027. The timing was notable: the deal landed just five days after the FDA approved Lantheus's TauClarify, a scan agent that identifies the tau protein tied to Alzheimer's. Lantheus withdrew its own full-year forecast when the deal was signed. The stock was still trading below the $102.50 cash price, normal for a deal that won't close until 2027.
• Eli Lilly (LLY), $3.8 billion of vaccine and infectious-disease acquisitions plus a CureVac partnership. Per the Telltales podcast, Lilly agreed to buy three vaccine and infectious-disease companies for a combined $3.8 billion and committed $50 million upfront to an mRNA cancer partnership with CureVac worth up to $1.8 billion, its clearest move yet to build a business line beyond metabolic and weight-loss drugs.
• Moderna (MRNA) and Merck, melanoma cancer vaccine progress. The Health:Further podcast noted Moderna's stock roughly doubled off a low base on strong data for its mRNA cancer vaccine for melanoma, used alongside Merck's Keytruda. Importantly, the hosts stressed this is not a "prevent-it" vaccine but a treatment that slows the cancer's return: "it extends life… like any oncology treatment." The Telltales podcast flagged Moderna's Phase III melanoma readout with Merck as a major event and previewed a capital-allocation comparison against BioNTech.
• Costco into Medicare Advantage. Via a partnership with SCAN Group, Costco is entering Medicare plan sales in three initial markets (per Health:Further).

(For context beyond healthcare, the Telltales podcast also covered Charter closing its $34.5 billion purchase of Cox Communications and Liberty Broadband, relevant to the broader market backdrop but not to the healthcare book.)

Regulatory watch

The big Medicaid squeeze (HR1). The most consequential regulatory thread of the week, explained in depth on the HIMSSCast podcast by Holland & Knight's Robert Bradner:

• Hospitals help fund their states' share of Medicaid through "provider taxes," currently capped at 6% of net patient revenue. Under HR1, that cap ramps down toward 3.5%, shrinking how much states can raise.
• "State Directed Payments," extra money that flows to hospitals serving lots of Medicaid patients, are currently allowed up to the average commercial insurance rate. The new law forces them down to "Medicare rates or… 110 percent of Medicare," which are much lower, phased in at roughly 10% a year for grandfathered states. These payments can be about 20% of a hospital's Medicaid revenue.
• New "community engagement" (work) requirements are expected to push people off Medicaid, meaning more uninsured patients and more unpaid hospital bills. The cuts start biting in about a year, and Bradner noted Washington could still "delay… or block" pieces of it, especially after the November election.

New FDA leadership. Per the Health:Further podcast, President Trump named Dr. Heidi Overton as the new FDA director, after previous commissioner Marty McCary departed (reportedly over a dispute involving flavored vapes). The hosts expect continuity on efficiency efforts but see ongoing tension between science and politics at the agency.

AI-device rules. The FDA (via device-strategy official Rick Abramson) put out draft guidelines for regulating generative-AI-enabled devices and opened a public comment period, shifting toward continuous post-launch monitoring rather than only heavy upfront testing (per Health:Further).

Drug approvals in the news this week, reported in the week's healthcare coverage:

• The FDA cleared a Roche/Eli Lilly blood test (Elecsys pTau217) to help identify Alzheimer's-related changes in people 55+ with cognitive decline (Aug 24).
• Revolution Medicines (RVMD) received FDA approval on Aug 27 for Rasonque (daraxonrasib) in metastatic pancreatic cancer, based on trial data showing a 60% reduction in the risk of death (median survival 13.2 vs. 6.7 months); it set the list price at $39,800 per 30-day supply.
• Moderna (MRNA) received FDA approval on Aug 27 for its updated 2026–2027 COVID-19 vaccine.
• Bristol-Myers Squibb (BMY) won accelerated approval for a relapsed/refractory multiple myeloma drug and committed $2.3 billion to expand U.S. manufacturing in Houston. (These items come from this week's press coverage rather than the podcasts; treat the specific figures as reported.)

State-level Medicaid tightening. California is slashing the asset limit for its Medi-Cal program from about $130,000 to $31,000 for a couple (and $21,000 for a single person), an 84% cut, in one of the more generous states (per Health:Further).

Premiums keep climbing. Kaplman cited an Aon estimate that employer health premiums are set to rise about 10% next year, on top of roughly 14% the year before, "tripling the rate of inflation again" (per Health:Further).

Week ahead, what to watch

• A Protagonist Therapeutics (PTGX) FDA decision, any day now. On the Schwab Network podcast, CEO Dinesh Patel said the FDA decision date for rasfertide, its blood-disorder drug for polycythemia vera, partnered with Takeda, is "just around the corner by the end of this month." A yes would give Protagonist a second approved drug this year (after Icotide, its J&J-partnered oral immune-disease pill approved in March). Patel noted the FDA has approved about 33 drugs so far this year, versus a typical 40–50.
• Medicare Advantage "annual enrollment" season begins. Plans for 2027 start being marketed in October. Given the record terminations described on The Seven Figures Or Bust podcast, watch how many seniors are displaced and which insurers (UnitedHealth, Humana) keep retreating, a direct read on managed-care earnings.
• The Medicaid payment cuts clock. The HR1 provider-tax and state-directed-payment reductions detailed on HIMSSCast begin phasing in over roughly the next year. Any move in Washington to delay or soften them (a real possibility around the midterms) would be a positive surprise for hospital operators like HCA, Tenet (THC), and Community Health Systems (CYH).
• Theralase regulatory filing. On the Stocks To Watch podcast, CEO Roger White said the company plans to submit its bladder-cancer therapy to Health Canada and the FDA under a rolling review later in 2026, targeting approval in 2027. Its reported results, a 65% complete-response rate, clear the bar cancer specialists set for widespread adoption, so the filing is the next catalyst for this small-cap name.
• Politics as a healthcare catalyst. With the November midterms approaching and affordability anger rising, keep an eye on healthcare-policy rhetoric, including, per the Health:Further podcast, whether "Medicare for All" gains real momentum. It's a low-probability but high-impact swing factor for the whole sector.